About this episode
Send a textCannabis just moved from Schedule I to Schedule III — and the biggest implications have nothing to do with lifestyle or politics.In this episode of Market Outsiders, Jenny Rae and Namaan break down what reclassification means for the market: who benefits, who loses, and why cannabis stocks dropped on “good” news.They unpack the real unlocks behind the headlines — Medicare and Medicaid eligibility, federally funded research, banking access, and why Big Pharma, consumer giants, and even beer companies may now have the edge.This is a regulatory shock case study: how one policy change reshapes competition, pricing power, supply chains, and long-term winners across healthcare and consumer markets.Partner Links:Learn more about NordStellar's Threat Exposure Management Program; unlock 10% off with code SIMPLIFIED-10Chapters:01:05 — What Cannabis Reclassification Actually Changes03:15 — Schedule I vs Schedule III: Why It Matters05:45 — Banking, Taxes, and the Industry’s Hidden Constraints08:20 — Medicare, Medicaid, and the Real Demand Unlock11:10 — Why Cannabis Stocks Fell on “Good” News13:30 — Big Pharma, Big Beer, and New Market Entrants19:40 — Supply Chains, Compliance, and Rising Costs25:00 — Who Wins, Who Loses, and What Comes NextMBB Undergrad Timelines Are This MonthApplication deadlines are the earliest we've ever seen; join Black Belt for an accelerated, MBB-led prep programConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementcons
